The question
Here’s a polished version with that additional context incorporated:
• Seeking a second opinion regarding persistent thin endometrial lining and whether there are any additional diagnostic or treatment options that may be worth considering.
• I experienced a miscarriage last year that required a D&C for retained products of conception. In May of this year, I underwent a hysteroscopy, during which intrauterine adhesions were identified and removed. Despite this, I continue to have persistently thin endometrial lining.
• My most recent FET cycle was cancelled due to inadequate endometrial development, following multiple mock transfer cycles with similar findings.
• My current RE feels we have exhausted most available treatment options and believes I may naturally have a thin endometrium, although it is unclear whether my prior pregnancy loss, D&C, or adhesions have contributed.
• During my IVF retrieval cycles, my lining measured approximately 5 mm in two cycles and 7.8 mm in one; however, my RE suspects the 7.8 mm measurement may have been inaccurate, as we’ve been unable to achieve anything close to that since.
• First mock cycle: completed the same month as my hysteroscopy using estrogen patches, vaginal estrogen suppositories, and oral estrogen. I’m unsure whether having recently undergone hysteroscopy may have affected the outcome or whether that cycle is representative.
• Second mock cycle: natural cycle using only baby aspirin (81 mg).
• Most recent FET attempt: treated with Pergoveris stimulation, with a maximum lining of 5.1 mm, which subsequently decreased despite continued monitoring, resulting in cancellation of the transfer.
• The current plan is to proceed with another FET cycle using vaginal estrogen (and possibly transdermal estrogen patches), with the goal of transferring if my lining reaches approximately 5 mm, rather than waiting for the more typical 7–8 mm.
• I have demonstrated a trilaminar endometrial pattern at approximately 4.9–5.0 mm.
• I have only two remaining PGT-SR tested embryos, so I want to ensure we have explored every reasonable option before proceeding.
Questions:
• Given my history of miscarriage, D&C, hysteroscopic adhesiolysis, and persistent thin lining, would you recommend any additional investigations to determine the underlying cause?
• Do you think the first mock cycle (performed the same month as my hysteroscopy) should be interpreted differently, or could the recent surgery have influenced the lining response?
• Are there any alternative protocols or therapies you would recommend that have not yet been explored?
• Based on the available evidence and your clinical experience, would you be comfortable proceeding with an embryo transfer at approximately 5 mm if the lining is trilaminar?
• Are there any additional factors you would consider before deciding whether to proceed with transfer versus continuing attempts to improve the lining?
Answer from Dr. Geoffrey Sher
WE would need to talk. Call Patti at 702-533-2691 or email her at conscierge@sherivf.com and set up an online consultation with me.
ANATOMICAL UTERINE CAUSES OF EMBRYO IMPLANTATION DYSFUNCTION
Why Good Embryos Sometimes Fail to Implant—and How Identifying Hidden Uterine Factors Can Transform IVF Failure into Success
SHER FERTILITY SOLUTIONS (SFS)
____________________________________________________________________________
Despite remarkable advances in assisted reproductive technology, implantation failure remains one of the most frustrating and misunderstood challenges confronting both patients and fertility specialists. Every year, countless women undergo in vitro fertilization (IVF) only to experience the disappointment of failed embryo transfers or recurrent pregnancy loss despite the transfer of seemingly healthy embryos. In many cases, these failures are attributed solely to embryo quality. While embryo-related abnormalities are unquestionably responsible for the majority of unsuccessful IVF cycles, they do not tell the whole story. Successful implantation requires not only a viable embryo but also a receptive uterine environment capable of supporting embryo attachment, invasion, and subsequent placental development.
This concept, known as implantation dysfunction, is frequently overlooked. Yet it may represent the missing explanation in a significant proportion of patients who experience repeated IVF failure, recurrent implantation failure, or otherwise unexplained pregnancy loss. Broadly speaking, implantation dysfunction can be divided into two major categories: anatomical factors involving the uterus itself and immunologic factors that interfere with the complex dialogue between the embryo and the maternal immune system.
This article focuses on anatomical uterine abnormalities that can prevent even healthy embryos from implanting successfully.
The Uterus: More Than a Passive Incubator
A common misconception is that once a healthy embryo reaches the uterus, pregnancy should naturally follow. In reality, implantation is one of the most complex biological events in human reproduction. During a brief and highly synchronized period known as the “window of implantation,” the embryo and endometrium engage in an intricate biochemical interaction that allows the embryo to attach to the uterine lining, establish a blood supply, and ultimately develop into a functioning placenta.
Any disruption of this process can compromise implantation. Such disruption may result from structural abnormalities within the uterine cavity, defects involving the endometrial lining, diminished blood flow to the uterus, or abnormalities that interfere with endometrial receptivity. The result may be repeated IVF failure despite the transfer of morphologically normal embryos.
Although approximately 80% of IVF failures are believed to result from embryo-related factors such as chromosomal abnormalities, age-related egg quality decline, the remaining 20% often arise from implantation dysfunction. Among these cases, anatomical uterine factors represent some of the most common and most treatable causes.
Surface Lesions Within the Uterine Cavity
The inner surface of the uterus is lined by the endometrium, a specialized tissue that undergoes cyclical hormonal changes in preparation for implantation. For successful implantation to occur, this surface must be smooth, healthy, and free of abnormalities that might interfere with embryo attachment.
Among the most common structural abnormalities are endometrial polyps, submucosal fibroids, intrauterine adhesions (scar tissue), retained placental tissue, and congenital uterine septa. While many of these lesions are benign, their impact on fertility can be substantial.
Fibroids provide an excellent example. Most fibroids do not adversely affect fertility and require no treatment. However, when fibroids distort the uterine cavity or protrude beneath the endometrial surface, they may significantly impair implantation. Even relatively small submucosal fibroids can alter local blood flow, provoke inflammatory changes, distort the implantation site, and interfere with the embryo’s ability to establish normal contact with the endometrium. Similarly, multiple fibroids within the uterine wall may compromise blood flow to the lining and impair normal endometrial development.
Endometrial polyps and intrauterine adhesions can have similar consequences. By occupying space within the cavity and provoking localized inflammation, these lesions may create an environment that is inhospitable to embryo implantation. Indeed, their effect has often been compared to that of an intrauterine contraceptive device (IUD), which prevents pregnancy through the creation of a localized inflammatory response. It is therefore not surprising that even relatively small uterine lesions can have a disproportionately large effect on reproductive outcome.
Because many of these abnormalities are readily identifiable and treatable, careful evaluation of the uterine cavity should be considered an essential component of fertility assessment, particularly before undertaking IVF.
Evaluating the Uterine Cavity
Several highly effective diagnostic techniques are available to evaluate the uterine cavity before IVF treatment.
Among the most useful is Hysterosonography, also known as saline infusion sonography. This procedure involves gently instilling sterile saline into the uterine cavity while performing transvaginal ultrasound. The saline distends the cavity, allowing the physician to visualize subtle abnormalities that might otherwise be missed. In experienced hands, Hysterosonography is highly sensitive for detecting polyps, fibroids, adhesions, septa, and other cavity defects. Because it is relatively inexpensive, minimally invasive, and generally well tolerated, it has become an invaluable tool in the evaluation of implantation failure.
Hysteroscopy remains the gold standard for direct assessment of the uterine cavity. Using a slender telescope inserted through the cervix, the physician can directly inspect the uterine lining and identify abnormalities that may interfere with implantation. Perhaps more importantly, hysteroscopy is not merely diagnostic; it is often therapeutic. Polyps can be removed, fibroids resected, adhesions divided, and septa corrected during the same procedure. In our experience, approximately one in eight women preparing for IVF is found to have a uterine abnormality significant enough to warrant correction prior to embryo transfer.
When the Problem Is the Uterine Lining (endometrium) Itself
Even when the uterine cavity appears completely normal, implantation may fail because the endometrial lining does not develop adequately. Over three decades ago, our team demonstrated a strong relationship between endometrial thickness and reproductive outcome. Using ultrasound measurements obtained during the late proliferative phase of the menstrual cycle, we found that implantation rates were closely linked to the thickness of the estrogen-stimulated endometrium.
An endometrial thickness greater than 9 mm was associated with optimal implantation potential, whereas thicknesses between 8 and 9 mm produced intermediate results. Once endometrial thickness fell below 8 mm, implantation rates declined dramatically and early pregnancy loss became increasingly common. Although viable pregnancies can occasionally occur with thinner linings, the likelihood decreases substantially as endometrial development becomes progressively compromised.
The biological explanation is straightforward. The endometrium consists of two distinct layers. The basal layer serves as the regenerative foundation from which the functional layer develops each month under the influence of estrogen. If the basal layer is damaged or unable to respond appropriately to hormonal stimulation, the functional layer cannot develop adequately, resulting in a thin, poorly receptive lining.
Several factors may contribute to this problem, including previous endometrial inflammation, infection, retained pregnancy tissue, surgical trauma from aggressive dilation and curettage procedures, prolonged exposure to anti-estrogenic medications such as clomiphene citrate, excessive ovarian androgen production, uterine fibroids, and adenomyosis. Regardless of the underlying cause, the final common pathway is diminished endometrial receptivity and impaired implantation potential.
The Viagra Connection: A Revolutionary Approach to a Thin Endometrium
One of the most significant advances in the treatment of thin endometrium emerged from an unexpected source. Sildenafil citrate, widely known by its trade name Viagra, became famous for its ability to increase penile blood flow in men with erectile dysfunction. Recognizing that the same mechanism might improve uterine blood flow, we began investigating whether vaginal administration of sildenafil could enhance delivery of estrogen to the endometrium and stimulate endometrial development.
The results were remarkable. Increased uterine blood flow translated into improved endometrial growth in a substantial proportion of women who had previously experienced repeated IVF failure associated with persistently thin linings. This work ultimately led to the birth of the world’s first so-called “Viagra baby” and opened an entirely new therapeutic avenue for women with implantation dysfunction.
Over subsequent years, thousands of women have been treated using this approach. Approximately 70–75% demonstrate significant improvement in endometrial thickness, often within only a few days of initiating therapy. Importantly, because sildenafil is administered vaginally, high concentrations reach the uterus before entering the systemic circulation, minimizing side effects while maximizing local effectiveness.
Not every patient responds, however. Women with severe and irreversible damage to the basal endometrium, often resulting from prior infection or extensive surgical trauma, may fail to show improvement despite enhanced blood flow. In such cases, the underlying regenerative capacity of the lining has been permanently compromised.
A Final Perspective
Repeated IVF failure should never be dismissed as bad luck, nor should it automatically be attributed to embryo quality alone. A healthy embryo requires a healthy uterine environment, and the failure to recognize correctable uterine abnormalities may condemn patients to repeated unsuccessful treatment cycles.
The encouraging reality is that many anatomical causes of implantation dysfunction can be identified and effectively treated. Whether the problem involves a subtle cavity lesion, a uterine fibroid, intrauterine scar tissue, or a persistently thin endometrial lining, recognition of the underlying abnormality often creates opportunities for intervention that can dramatically improve reproductive outcome.
For many patients, the embryo is not the problem. The challenge lies in creating the optimal environment in which that embryo can implant, grow, and ultimately become the healthy baby they have long hoped to bring into the world.
/////////////////////////////////////////////////////////
General information only, not medical advice for your own situation. For that, book a consultation.